Amicus Therapeutics Dividends
| FOLD Stock | USD 14.30 0.01 0.07% |
The current year's Dividends Paid is expected to grow to about 5.5 M, whereas Dividend Paid And Capex Coverage Ratio is forecasted to decline to (11.52). Amicus Therapeutics' past performance could be the main factor of why investors trade Amicus Therapeutics stock today. Investors should clearly understand every aspect of the Amicus Therapeutics dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Amicus Therapeutics' dividend schedule and payout information. Amicus Therapeutics dividends can also provide a clue to the current valuation of Amicus Therapeutics.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 5 M | 5.5 M | |
| Dividend Paid And Capex Coverage Ratio | (10.97) | (11.52) |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Amicus Therapeutics must own a stock before its ex-dividend date to receive its next dividend.
Amicus Therapeutics Dividends Paid Over Time
Today, most investors in Amicus Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Amicus Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Amicus Therapeutics dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Will Biotechnology sector continue expanding? Could Amicus diversify its offerings? Factors like these will boost the valuation of Amicus Therapeutics. Market participants price Amicus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Amicus Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.04) | Revenue Per Share | Quarterly Revenue Growth 0.195 | Return On Assets | Return On Equity |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Amicus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.